Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01335009
Registration number
NCT01335009
Ethics application status
Date submitted
14/03/2011
Date registered
13/04/2011
Date last updated
1/09/2021
Titles & IDs
Public title
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
Query!
Scientific title
A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects With Metastatic Melanoma
Query!
Secondary ID [1]
0
0
2011-001282-40
Query!
Secondary ID [2]
0
0
MORAb-004-201MEL
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - MORAb-004 (monoclonal antibody)
Experimental: MORAb-004, 2 mg/kg - Biologic (monoclonal antibody)
Experimental: MORAb-004, 4 mg/kg - Biologic (monoclonal antibody)
Other interventions: MORAb-004 (monoclonal antibody)
Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Progression-free Survival (PFS) at Week 24
Query!
Assessment method [1]
0
0
PFS was defined as the time (in weeks) from the date of randomization to the date of the first sign of disease progression (PD) based on Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1, or date of death, regardless of cause. PD greater than or equal to (>=) 20 percent (%) increase in the nadir of total tumor burden (TTB) (minimum 5 millimeter [mm]). Participants who were alive with no disease progression had their PFS time censored at the date of their last tumor assessment. Participants who received a new anti-cancer therapy before disease progression had their PFS time censored at the date of their last tumor assessment before the new anti-cancer therapy was started. PFS was analyzed using Kaplan Meier method.
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [1]
0
0
Percentage of Participants With PFS at Weeks 16 and 52
Query!
Assessment method [1]
0
0
PFS was defined as the time (in weeks) from the date of randomization to the date of the first observation of PD (RECIST version 1.1) or date of death, regardless of the cause. PD >=20% increase in the nadir of TTB (minimum 5 mm). Participants who were alive with no disease progression had their PFS time censored at the date of their last tumor assessment. Participants who received new anti-cancer therapy before disease progression had their PFS time censored at the date of their last tumor assessment before the new anti-cancer therapy was initiated. PFS was based on the Kaplan-Meier method.
Query!
Timepoint [1]
0
0
Week 16 and Week 52
Query!
Secondary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS was defined as the time (in weeks) from the date of randomization to the date of death, regardless of cause. In the absence of death confirmation, or for participants alive at the time of analysis, the survival time was censored at the date of the last study follow-up. OS was calculated using the Kaplan-Meier method. As per planned analysis, efficacy outcomes was planned to be analyzed until cut-off date (02 December 2013).
Query!
Timepoint [2]
0
0
Date of first study treatment (Day 1) to date of death or up to approximately 2 years 7 months
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Overall Response
Query!
Assessment method [3]
0
0
ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) that occurred (defined by RECIST version 1.1) using CT/MRI. Per RECIST 1.1, CR= disappearance of all lesions; PR greater than or equal to (>=) 30percent (%) decrease from baseline in TTB. As per planned analysis, efficacy outcomes was planned to be analyzed until cut-off date (02 December 2013).
Query!
Timepoint [3]
0
0
Date of first study treatment (Day 1) to complete response or partial response, assessed up to approximately 2 years 7 months
Query!
Secondary outcome [4]
0
0
Optimal Biologic Dosing (OBD) of Morab-004
Query!
Assessment method [4]
0
0
OBD is defined as the dose level/exposure level at which three parameters are met: 1) adequate pharmacokinetic (PK) profile with a serum half-life (t1/2) of >=48 hours, 2) at least minimal demonstration of antitumor efficacy (50% or greater PFS rate at 16 weeks), and 3) change of 25% or greater from baseline value in any of the pharmacodynamic (PD) parameters assessed in the study in 30% of participants at that dose level.
Query!
Timepoint [4]
0
0
Day 1 Cycle 1 (Cycle length = 28 days)
Query!
Eligibility
Key inclusion criteria
- Be surgically sterile or consent to use a medically acceptable method of contraception
throughout the study period.
- Histologically confirmed diagnosis of metastatic melanoma
- At least 1 prior systemic treatment for metastatic melanoma with disease progression
following treatment
- Measurable disease, as defined by RECIST v1.1, assessed within 4 weeks prior to study
entry
- At least 3 week interval between first infusion of test article and most recent prior
systemic anticancer therapy. All treatment-associated toxicity must be resolved to
less than or equal to Grade 1 before the administration of MORAb-004
- Have a life expectancy of at least 3 months as estimated by the investigator
- Have other significant medical conditions well-controlled and stable, in the opinion
of the investigator, for at least 30 days prior to Study Day 1
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Have sites of disease amenable to the protocol-specified biopsy (Note: All
participants will have protocol-specified biopsy at Screening. The second,
on-treatment biopsy will be mandatory in the first 30 randomized participants only.
For all other participants, the second biopsy is optional.
- Laboratory tests results prior to Study Day 1 within limits as outlined in protocol
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Have received no prior systemic treatment for metastatic melanoma
- Evidence of other active malignancy requiring treatment within the last 5 years (other
than basal cell or squamous cell carcinoma of the skin), or active brain metastasis
- Clinically significant heart disease (Congestive heart failure of New York Heart
Association [NYHA] Class 3 or 4, angina not well controlled by medication, or
myocardial infarction within 6 mos.), or ECGs demonstrating clinically significant
arrhythmias
- Have any other serious systemic disease, including active bacterial or fungal
infection, or any medical condition requiring cytotoxic therapy or chronic (at least 4
consecutive weeks) systemic corticosteroid use
- Have active viral hepatitis or symptomatic Human immunodeficiency virus (HIV)
infection
- Be breast-feeding, pregnant, or likely to become pregnant during the study
- Known allergic reaction to a prior monoclonal antibody therapy
- Previous treatment with MORAb-004
- Brain metastasis
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/05/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
10/04/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
76
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
Sydney Cancer Center - Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [2]
0
0
Newcastle Melanoma Unit, Calvery Mater Newcastle - Waratah
Query!
Recruitment hospital [3]
0
0
The Crown Princess Mary Cancer Centre, Westmead Hospital - Westmead
Query!
Recruitment hospital [4]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Minnesota
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Jersey
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Utah
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Essen
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Mainz
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Tuebingen
Query!
Country [17]
0
0
United Kingdom
Query!
State/province [17]
0
0
London
Query!
Country [18]
0
0
United Kingdom
Query!
State/province [18]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eisai Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a global, Phase 2, open label, dose selection, proof-of-concept study to assess
progression free survival in subjects with metastatic melanoma.
Approximately 80 subjects at 29 sites in the U.S., U.K., Germany and Australia will be
randomized into one of two dose groups: 2 mg/kg, 4 mg/kg. Weekly treatment will continue
until disease progression.
Subjects must have measurable disease by CT Scan or MRI and must have completed at least one
prior round of chemotherapy.
Subjects will be assessed for Efficacy, PK/PD, Overall survival, and Safety (Adverse
Events/Adverse Events of Interest, Electrocardiograms (ECG's), clinical labs, physical
exams/vital signs, tolerability).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01335009
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01335009
Download to PDF